Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples